✦ LIBER ✦

Metronomic Oral Cyclophosphamide in Patients with Advanced Solid Tumors

✍ Scribed by Bojko, Peter; Schimmel, Gudrun; Bosse, Daniel; Abenhardt, Wolfgang

Book ID: 120644675
Publisher: S. Karger AG
Year: 2012
Tongue: English
Weight: 218 KB
Volume: 35
Category: Article
ISSN: 0378-584X
DOI: 10.1159/000336144

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY P

METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER

✍ Andrea Fontana; Guido Bocci; Luca Galli; Manolo D'Arcangelo; Lisa Derosa; Anna F 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

1484 PUBLICATION A metronomic treatment

1484 PUBLICATION A metronomic treatment with oral vinorelbine in poor performance status patients with pretreated solid tumors

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Metronomic Cyclophosphamide and Capecita

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

✍ Mayer, E.L. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 154 KB

A phase I study of oral ixabepilone in p

A phase I study of oral ixabepilone in patients with advanced solid tumors

✍ Deeken, John F.; Marshall, John L.; Pishvaian, Michael J.; Hwang, Jimmy; Ahlers, 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 278 KB

Oral Metronomic Cyclophosphamide and Met

Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report

✍ Gaetano Aurilio; Elisabetta Munzone; Edoardo Botteri; Angela Sciandivasci; Laura 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Antiangiogenetic therapy with pioglitazo

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

✍ Thomas Vogt; Christian Hafner; Klaus Bross; Frauke Bataille; Karl-Walter Jauch; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB

## Abstract ## BACKGROUND Systemic therapy options for patients with advanced angiosarcomas are limited, and their prognosis is poor. The idea of angiostatic therapy following the paradigm of metronomic dosed chemotherapeutics combined with proapoptotic biomodulators had not been considered previo